Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study

Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study

Muhammad Khan,1,2 Zhihong Zhao,3 Xianming Li,1 Guixiang Liao1 1Department of Oncology, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, People’s Republic of China; 2Department of Oncology, First Affiliated Hospital of Anhui Medical Uni...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Khan M, Zhao Z, Li X, Liao G
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
brain metastasis (bm)
whole brain radiation therapy (wbrt)
non-small cell lung cancer (nsclc)
immune checkpoint blockade (icb)
combination (combined) therapy
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/7c9493d3c20f46c188856410c2c514ec
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7c9493d3c20f46c188856410c2c514ec
record_format dspace
spelling oai:doaj.org-article:7c9493d3c20f46c188856410c2c514ec2021-11-25T18:55:29ZAnti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study1178-7074https://doaj.org/article/7c9493d3c20f46c188856410c2c514ec2021-11-01T00:00:00Zhttps://www.dovepress.com/anti-pd1-therapy-plus-whole-brain-radiation-therapy-may-prolong-pfs-in-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Muhammad Khan,1,2 Zhihong Zhao,3 Xianming Li,1 Guixiang Liao1 1Department of Oncology, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, People’s Republic of China; 2Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People’s Republic of China; 3Department of Nephrology, Shenzhen People’s Hospital, Second Clinical Medicine Centre, Jinan University, Shenzhen, People’s Republic of ChinaCorrespondence: Guixiang Liao; Xianming LiDepartment of Radiation Oncology, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, People’s Republic of ChinaEmail liaoguixiang@163.com; chenlhnfy@163.comBackground: Whole-brain radiotherapy (WBRT) remains an essential modality of treatment for brain metastases (BMs) derived from non-small cell lung cancer (NSCLC) patients and anti-PD-1 therapy has demonstrated intracranial responses in these patients. We aimed to evaluate if the combination of the two treatments could yield additive efficacy.Methods: A retrospective review of our institution’s database was carried out to identify NSCLC patients with BMs who had been treated with anti-PD1 therapy and/or WBRT between 2015 and 2020. Patient characteristics, main outcomes, including progression-free survival (PFS) and overall survival (OS), and factors affecting these outcomes were analyzed. SPSS 24 was used for statistical analysis. Appropriate statistical tests were employed according to the type of data.Results: Overall, 21 NSCLC BM patients were identified that had received WBRT. Of these, ten had been additionally treated with anti-PD1 therapy within 30 days of WBRT initiation. Median PFS was 3 (95% CI 0.8– 5.1) months with WBRT alone versus 11 (95% CI 6.3– 15.6) months with combined treatment. Risk of disease progression was 71% lower with the combined approach (HR 0.29, 95% CI 0.11– 0.80; p=0.016). A trend toward improved OS was also observed with the combined approach (HR 0.33, 95% CI 0.08– 1.12; p=0.107). Concurrent treatment (p=0.028) and male sex (p=0.052) were associated with improved PFS, while OS was associated only with age (p=0.02).Conclusion: Concurrent WBRT and anti-PD1 therapy may delay progression and improve survival in BM patients with confirmed EGFR- and ALK-negative NSCLC histology. Prospective studies are warranted to validate and elucidate on the additive effect of the two modalities.Keywords: brain metastasis, BM, whole-brain radiation therapy, WBRT, non–small cell lung cancer, NSCLC, immune checkpoint blockade, ICB, combination, combined therapyKhan MZhao ZLi XLiao GDove Medical Pressarticlebrain metastasis (bm)whole brain radiation therapy (wbrt)non-small cell lung cancer (nsclc)immune checkpoint blockade (icb)combination (combined) therapyMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 8903-8918 (2021)
institution DOAJ
collection DOAJ
language EN
topic brain metastasis (bm)
whole brain radiation therapy (wbrt)
non-small cell lung cancer (nsclc)
immune checkpoint blockade (icb)
combination (combined) therapy
Medicine (General)
R5-920
spellingShingle brain metastasis (bm)
whole brain radiation therapy (wbrt)
non-small cell lung cancer (nsclc)
immune checkpoint blockade (icb)
combination (combined) therapy
Medicine (General)
R5-920
Khan M
Zhao Z
Li X
Liao G
Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
description Muhammad Khan,1,2 Zhihong Zhao,3 Xianming Li,1 Guixiang Liao1 1Department of Oncology, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, People’s Republic of China; 2Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People’s Republic of China; 3Department of Nephrology, Shenzhen People’s Hospital, Second Clinical Medicine Centre, Jinan University, Shenzhen, People’s Republic of ChinaCorrespondence: Guixiang Liao; Xianming LiDepartment of Radiation Oncology, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, People’s Republic of ChinaEmail liaoguixiang@163.com; chenlhnfy@163.comBackground: Whole-brain radiotherapy (WBRT) remains an essential modality of treatment for brain metastases (BMs) derived from non-small cell lung cancer (NSCLC) patients and anti-PD-1 therapy has demonstrated intracranial responses in these patients. We aimed to evaluate if the combination of the two treatments could yield additive efficacy.Methods: A retrospective review of our institution’s database was carried out to identify NSCLC patients with BMs who had been treated with anti-PD1 therapy and/or WBRT between 2015 and 2020. Patient characteristics, main outcomes, including progression-free survival (PFS) and overall survival (OS), and factors affecting these outcomes were analyzed. SPSS 24 was used for statistical analysis. Appropriate statistical tests were employed according to the type of data.Results: Overall, 21 NSCLC BM patients were identified that had received WBRT. Of these, ten had been additionally treated with anti-PD1 therapy within 30 days of WBRT initiation. Median PFS was 3 (95% CI 0.8– 5.1) months with WBRT alone versus 11 (95% CI 6.3– 15.6) months with combined treatment. Risk of disease progression was 71% lower with the combined approach (HR 0.29, 95% CI 0.11– 0.80; p=0.016). A trend toward improved OS was also observed with the combined approach (HR 0.33, 95% CI 0.08– 1.12; p=0.107). Concurrent treatment (p=0.028) and male sex (p=0.052) were associated with improved PFS, while OS was associated only with age (p=0.02).Conclusion: Concurrent WBRT and anti-PD1 therapy may delay progression and improve survival in BM patients with confirmed EGFR- and ALK-negative NSCLC histology. Prospective studies are warranted to validate and elucidate on the additive effect of the two modalities.Keywords: brain metastasis, BM, whole-brain radiation therapy, WBRT, non–small cell lung cancer, NSCLC, immune checkpoint blockade, ICB, combination, combined therapy
format article
author Khan M
Zhao Z
Li X
Liao G
author_facet Khan M
Zhao Z
Li X
Liao G
author_sort Khan M
title Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
title_short Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
title_full Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
title_fullStr Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
title_full_unstemmed Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
title_sort anti-pd1 therapy plus whole-brain radiation therapy may prolong pfs in selected non–small cell lung cancer patients with brain metastases: a retrospective study
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/7c9493d3c20f46c188856410c2c514ec
work_keys_str_mv AT khanm antipd1therapypluswholebrainradiationtherapymayprolongpfsinselectednonndashsmallcelllungcancerpatientswithbrainmetastasesaretrospectivestudy
AT zhaoz antipd1therapypluswholebrainradiationtherapymayprolongpfsinselectednonndashsmallcelllungcancerpatientswithbrainmetastasesaretrospectivestudy
AT lix antipd1therapypluswholebrainradiationtherapymayprolongpfsinselectednonndashsmallcelllungcancerpatientswithbrainmetastasesaretrospectivestudy
AT liaog antipd1therapypluswholebrainradiationtherapymayprolongpfsinselectednonndashsmallcelllungcancerpatientswithbrainmetastasesaretrospectivestudy
_version_ 1718410532703174656

Ejemplares similares